Compare GVH & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | FEMY |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 12.0M |
| IPO Year | 2023 | 2021 |
| Metric | GVH | FEMY |
|---|---|---|
| Price | $0.99 | $3.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $80.00 | $5.50 |
| AVG Volume (30 Days) | ★ 1.1M | 44.0K |
| Earning Date | 02-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | $102,768.97 | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $0.87 | $0.29 |
| 52 Week High | $7.19 | $6.29 |
| Indicator | GVH | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 28.78 | 53.59 |
| Support Level | N/A | $3.50 |
| Resistance Level | $1.79 | $4.78 |
| Average True Range (ATR) | 0.47 | 0.42 |
| MACD | -0.41 | -0.08 |
| Stochastic Oscillator | 2.20 | 60.00 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.